ImmunoGen: Profiting And Turning Around

11/13/19

By BioSci Capital Partners, SeekingAlpha

Summary

  • This year, ImmunoGen suffered multiple setbacks, both from the clinical and regulatory fronts. Amid these difficulties, there are stellar opportunities to capture mega-profits.
  • ImmunoGen gambled with FORWARD 1 data to seek accelerated approval for Mirve. It didn't pay off so the company is running a new Phase 3 MIRASOL trial for this franchise.
  • MIRASOL is on track to enroll patients by year-end. I expect stellar results from this development. Moreover, I believe that the stock will continue to successfully turn around.
  • I do much more than just articles at Integrated BioSci Investing: Members get access to model portfolios, regular updates, a chat room, and more. Get started today ยป

The largest profits in the investment field go to those who are capable of correctly zigging when the financial community is zagging. - Phillip Fisher

In bioscience investing, a turnaround stock is certainly not for everyone. For a turnaround company, the lucrative profits arrive at the cost of an extremely high "investment risk score." To minimize the abnormal risks, it's helpful to have an expert edge, i.e. an advantage in navigating this uncertainty. Nonetheless, an expert edge alone is not adequate. In other words, you need to have a "strong stomach." I don't mean the six-packs of rectus abdominis. Rather, it's the instinct to go against the crowd when the data is screaming at you. Now it's easy to say that you're a contrarian but the reality is different. This is because you naturally don't go against the crowd because, at a young age, you're socially conditioned to conform. When you're a child, you learn to conform to your peers and when you're older you follow corporate expectations. But having the wisdom to walk your own path that sometimes diverges often leads you to the Promised Land of mega-profits.

The turnaround story of 2019 that epitomizes the aforesaid phenomenon is ImmunoGen (IMGN). Despite being knocked down with an ambiguous data release for Mirve and a failed regulatory binary, ImmunoGen is making a vigorous comeback going into 2020. In this research, I'll update investors with the latest fundamental developments and provide my expectations on this growth story.

Figure 1: ImmunoGen chart (Source: StockCharts)

READ FULL ARTICLE HERE